Study Phase 2

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis

  • PDF icon for CSR Summary CSR Summary Not Available
  • Globe symbol for NCT Number NCT04021862
  • Notebook for Primary Citation Primary Citation Trial has yet to be published
  • Spreadsheet for Data Specification Data Specification Not Available

Trial Information

Generic NameBermekimabProduct NameTherapeutic AreaImmune System DiseasesEnrollment86% FemaleN/A% WhiteN/A
Product ClassMonoclonal AntibodySponsor Protocol Number77474462ADM2002Data PartnerJohnson & JohnsonCondition StudiedAtopic, DermatitisMean/Median Age (Years)N/A

Supporting Documentation

  • Collected Datasets Available
  • Protocol with Amendments Available
  • Analysis Datasets Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.